Target intelligence / Profile preview

Bluetongue virus serotype 3 (BTV-3)

Target
BTV-3
Molecular classification
Virus, Double-stranded RNA virus, Genus Orbivirus, Family Sedoreoviridae (formerly Reoviridae before taxonomic update), Non-enveloped virus
01

Overview

Bluetongue virus serotype 3 (BTV-3) is a double-stranded RNA virus of the genus Orbivirus and family Sedoreoviridae. It is one of at least 36 officially characterized serotypes that cause Bluetongue disease, an acute, sometimes fatal, disease of ruminants primarily affecting sheep and cattle. BTV-3 contains a segmented genome encoding multiple structural (VP1–VP7) and non-structural proteins (NS1–NS5). Its serotype is determined chiefly by segment 2, which encodes the highly variable VP2 protein responsible for serotype specificity and is the principal target for neutralizing antibodies. The geographic spread of BTV-3 includes Africa, the Mediterranean Basin, North America (western topotype), and Asia-Pacific (eastern topotype), with reassortment and mutation contributing to its emergence in new regions. Disease outbreaks are typically associated with transmission by Culicoides biting midges, with vaccination strategies providing the main control but challenged by the virus’s genetic diversity and reassortment capabilities.

Other names
BTV-3Bluetongue virus type 3Bluetongue serotype 3
02

Mechanism of action

Vaccines: Induce immunity against virus capsid proteins that determine serotype specificity (VP2 and VP5). No classic "mechanism of action" as for therapeutic targets.

03

Biological functions

Infection of ruminants (primarily sheep, cattle, goats)Induction of immune response by infected hostTransmission by Culicoides (biting midges)Genetic reassortment and antigenic variability
04

Disease associations

Infection (specifically Bluetongue disease in ruminants)Emerging and re-emerging infectious disease (noted especially in Europe, Mediterranean basin, and elsewhere)
05

Safety considerations

Rapid genetic reassortment leading to vaccine escape or emergence of novel serotypesChallenges in vaccine matching due to high antigenic diversity among serotypesEconomic losses due to outbreaks in livestockTransmission facilitated by vector Culicoides species
06

Interacting drugs

None directly approved; no specific antiviral drugs are approved for BTV-3. Control is mainly through vaccination
07

Biomarkers

Viral RNA (detected by PCR targeting segment 2 for serotype specificity)Antibodies against Bluetongue virus detected by serological assays

Beyond the preview

Go deeper on Bluetongue virus serotype 3 (BTV-3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bluetongue virus serotype 3 (BTV-3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call